216例特发性膜性肾病临床、病理与治疗分析

《216例特发性膜性肾病临床、病理与治疗分析》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、万方数据sDecifictreatment，thedifferencewasstatisticallysignificant(P<0．05)．(3)Comparingtheeffectsofthreekindsofhormonecombinedwithsecond—lineimmunosuppressivetherapy：hormonecombinedwithtacrolimusgroup，withcyclophosphamidegroup，withcyclosporineAgrouphavenostatisticallysignificantdifference．(P>0．

2、05)．(4)Themainreasonforreplacingplaniscurativeeffectispoor,whichaccountingfor80．O％，(5)Thesizeoftheriskf．actorswhichhaveaneffectonthetreatmentisasfollows：renalinsufficiency,mesangialproliferation，renalvascularlesions，focalsegmentalsclerosislesions，glomerularsclerosislesions．Conclusion：(I)Pat

3、ientswithidiopathicmembranousnephropathywerefrequentlyseeninmiddle—agedpatients．(2)Theclinicalmanifestationofidiopathicmembranousnephropathywithhypertension，hyperlipidemiainpatientshaveahigherproportion．Withtheincreaseofage，globulin,creatinine，llreanitrogenlevelofidiopathicmembranousnephrop

4、athypatientsincreased，buteGFRdecreased．Theproportionofpatientswithhypertensionincreasedwithage．(3)mostPathologicalchangesisstagingofI，II．differentgender，agehavedifferentconstituentratioofpathologicalstage．(4)Hormonecombinedwithimmunosuppressanttherapyisatreatmentforidiopathicmembranousnephr

5、opathytreatmentcommonlyusedinourdepartment．Treatmentofhormonecombinedwithimmunosuppressantissuperiortonon—specifictreatment．(5)Theinformationofthisgroupcuethatthreekindsofhormonecombinedwithimmunosuppressant(P+CTX、P+TAC、P+CsA)tothetreatmentofidiopathicmembranousnephropathyhavenosignificantd

6、ifference．(6)Thesortofriskfactorsoftreatmentasfollows：renalinsufficiency，mesangialproliferation，renalvascularlesions，focalsegmentalsclerosislesions，glomerularsclerosislesions．Keyword：Idiopathicmembranousnephropathy，Clinicalcharacteristics，treatmentplan，Curativeeffect万方数据图表索引(一)表卜1216例特发性膜性肾

7、病各年龄组构成比···················08表卜2不同性别组年龄比较·······-··························09表2-1各年龄组体重指数比较·································10表2—2不同性别组体重指数比较·······························11表3216例患者的临床表现···································12表4各年龄段临床表现····················